Chemours (CC) SVP Kristine Wellman reports stock grant and tax withholding moves

Rhea-AI Filing Summary

Chemours Co senior vice president and general counsel Kristine M. Wellman reported routine equity compensation transactions in company common stock. She acquired 1,781 shares at no cost through performance stock units granted under the Long Term Incentive Plan, which vested after the compensation committee certified performance conditions were met.

To cover related tax obligations on vesting restricted stock units and dividend equivalent units, 675 shares were automatically withheld at a price of $18.41 per share; the footnotes state no shares were sold on the market. After these transactions and an adjustment correcting a prior administrative error, her directly owned, restricted stock unit, and dividend equivalent unit holdings total 51,401.6057 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wellman Kristine M

(Last) (First) (Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GC & Corp. Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		1,781(1)	A	$0	52,076.6057(2)	D
Common Stock	02/24/2026		F		675(3)	D	$18.41	51,401.6057(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were granted to the Reporting Person as performance stock units under the Company's Long Term Incentive Plan as part of 2023 compensation and vested subject to the satisfaction of certain performance conditions, which the Company's Compensation and Leadership Development Committee certified as having occurred.

2. The total holdings have been adjusted to correct an administrative error in prior Form 4s.

3. Shares automatically withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. Transactions are exempt from Section 16(b) pursuant to Rule 16b-3. No shares were sold.

4. Includes directly owned shares, restricted stock units and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Chemours (CC) executive Kristine Wellman report?

Kristine Wellman reported routine equity compensation activity, including a grant of 1,781 Chemours common shares via vested performance stock units and an automatic withholding of 675 shares to satisfy tax obligations on vesting restricted stock units and dividend equivalent units, with no open-market sales disclosed.

Were any Chemours (CC) shares sold on the open market in this Form 4?

No open-market sales were reported. The 675 Chemours shares shown as a disposition were automatically withheld to satisfy tax obligations on vesting equity awards, and the filing explicitly notes that no shares were sold, with the transaction exempt under Rule 16b-3.

How many Chemours (CC) shares did Kristine Wellman acquire through equity awards?

She acquired 1,781 Chemours common shares at no cost through vested performance stock units granted under the company’s Long Term Incentive Plan as part of 2023 compensation, after the Compensation and Leadership Development Committee certified that required performance conditions had been satisfied.

What is Kristine Wellman’s Chemours (CC) shareholding after these Form 4 transactions?

After the reported transactions and an adjustment correcting an administrative error in earlier filings, Kristine Wellman’s holdings total 51,401.6057 Chemours shares, including directly owned common stock, restricted stock units, and dividend equivalent units, as described in the ownership footnote in the Form 4.

Why were 675 Chemours (CC) shares listed as a disposition in the Form 4?

The 675-share disposition reflects shares automatically withheld at $18.41 per share to satisfy tax obligations related to vesting restricted stock units and dividend equivalent units, and the filing clarifies that these withholding transactions involved no open-market sale of Chemours stock by the reporting person.

What do the footnotes in Kristine Wellman’s Chemours (CC) Form 4 explain?

The footnotes explain that the new shares came from vested performance stock units tied to 2023 compensation, clarify that shares were withheld solely for tax obligations with no sales, note a correction of an administrative error, and confirm holdings include common shares, restricted units, and dividend equivalents.